Javascript must be enabled to continue!
Design, Formulation Development and Characterization of Empagliflozin Nanosuspension
View through CrossRef
To develop empaglifazon nanosuspension by Solvent evaporation technique using ethanol as organic phase then aqueous phase was prepared by dissolving acetate cellulose in water then add poloxamer-188 and sodium lauryl sulphate. Physicochemical properties like melting point, solubility, particle size and shape, in-vitro diffusion studies etc. were performed for the prepared nanosuspension formulations. Based on drug excipient compatibility studies such as FTIR images shown that there is no interaction between drug and excipients. XRD studies revealed the crystalline structure of the formulation. A surface characteristic was determined by SEM. In-vitro diffusion studies were carried out by Franz diffusion cell, found the ranges around 95% for both pure and optimized formulations. Research indicates that the Empagliflozin nanosuspension is optimal for prolonged and extended release. This nanosuspension has been found to effectively reduce diabetes mellitus when taken orally.
Title: Design, Formulation Development and Characterization of Empagliflozin Nanosuspension
Description:
To develop empaglifazon nanosuspension by Solvent evaporation technique using ethanol as organic phase then aqueous phase was prepared by dissolving acetate cellulose in water then add poloxamer-188 and sodium lauryl sulphate.
Physicochemical properties like melting point, solubility, particle size and shape, in-vitro diffusion studies etc.
were performed for the prepared nanosuspension formulations.
Based on drug excipient compatibility studies such as FTIR images shown that there is no interaction between drug and excipients.
XRD studies revealed the crystalline structure of the formulation.
A surface characteristic was determined by SEM.
In-vitro diffusion studies were carried out by Franz diffusion cell, found the ranges around 95% for both pure and optimized formulations.
Research indicates that the Empagliflozin nanosuspension is optimal for prolonged and extended release.
This nanosuspension has been found to effectively reduce diabetes mellitus when taken orally.
Related Results
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge worldwide and is a pressing public health issue in Pakistan. Patients here often present at ...
Novel biomarkers in cardiovascular disease and dysglycaemia
Novel biomarkers in cardiovascular disease and dysglycaemia
<p dir="ltr"><b>Background</b><b>.</b> Cardiovascular disease (CVD) and dysglycaemia are closely interconnected. Dysglycaemia, defined as impaired glu...
Novel biomarkers in cardiovascular disease and dysglycaemia
Novel biomarkers in cardiovascular disease and dysglycaemia
<p dir="ltr"><b>Background</b><b>.</b> Cardiovascular disease (CVD) and dysglycaemia are closely interconnected. Dysglycaemia, defined as impaired glu...
Implementation Of Box Behnken Design To Fabricate The Formulation, Optimization And Dissolution Of Blueberry Nanosuspension
Implementation Of Box Behnken Design To Fabricate The Formulation, Optimization And Dissolution Of Blueberry Nanosuspension
The present study aims to enhance the bioavailability of Blueberry by formulating it as nanosuspension. Blueberry mainly consists ofanthocyanins which have strong antihyperlipidemi...
Ultrasonic modification for stabilizing Lantana camara nanosuspension emulsification
Ultrasonic modification for stabilizing Lantana camara nanosuspension emulsification
The preparation of emulsification by low-energy phase inversion is an appropriate method for providing a nanosuspension of Lantana camara Ethyl Acetate Fraction (EAF) dispersed in ...
Abstract 4144446: Efficacy and Safety of Empagliflozin after Acute Myocardial Infarction: A Systematic Review and Meta Analysis
Abstract 4144446: Efficacy and Safety of Empagliflozin after Acute Myocardial Infarction: A Systematic Review and Meta Analysis
Introduction:
Empagliflozin, a sodium–glucose co-transporter-2 (SGLT-2) inhibitor, improves cardiovascular outcomes in patients with heart failure (HF) with or without ...
Effectiveness of SGLT2 inhibitor (Empagliflozin) in reduction of albuminuria in type 2 Diabetics
Effectiveness of SGLT2 inhibitor (Empagliflozin) in reduction of albuminuria in type 2 Diabetics
Introduction: Diabetic kidney dysfunction is a leading cause of end-stage renal disease (ESRD) globally. Empagliflozin is a highly selective inhibitor of sodium-glucose cotransport...
Development and characterization of acemetacin nanosuspension-based oral lyophilisates
Development and characterization of acemetacin nanosuspension-based oral lyophilisates
Acemetacin is a non-steroidal anti-inflammatory drug (NSAIDs) which has an analgesic, antipyretic, and anti-inflammatory effect. The aim of the present study was to develop oral ly...

